A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair–Deficient/Microsatellite Instability–High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer

PURPOSE: We evaluated the efficacy and safety of avelumab, an anti-PD-L1 antibody, in patients with metastatic or unresectable colorectal cancer (mCRC) with mismatch repair deficiency (dMMR)/microsatellite instability-high (MSI-H) or POLE mutations. MATERIALS AND METHODS: In this prospective, open-l...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jwa Hoon, Kim, Sun Young, Baek, Ji Yeon, Cha, Yong Jun, Ahn, Joong Bae, Kim, Han Sang, Lee, Keun-Wook, Kim, Ji-Won, Kim, Tae-You, Chang, Won Jin, Park, Joon Oh, Kim, Jihun, Kim, Jeong Eun, Hong, Yong Sang, Kim, Yeul Hong, Kim, Tae Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577804/
https://www.ncbi.nlm.nih.gov/pubmed/32340084
http://dx.doi.org/10.4143/crt.2020.218

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577804/
https://www.ncbi.nlm.nih.gov/pubmed/32340084
http://dx.doi.org/10.4143/crt.2020.218

Ejemplares similares